Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company developing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic, colorectal and lung cancers. Using its proprietary lymph node-targeted Amphiphile (AMP) technology, the company engineers off-the-shelf therapeutic cancer vaccines and immunomodulators designed to activate and amplify cancer-fighting T cells and promote durable cancer immunosurveillance. Its lead candidate, ELI-002, targets the most common KRAS mutations that drive many solid tumors.